Clinical study of Qi-Shen Yi-Qi dropping pill in the treatment of acute myocardial infarction patient with Qi-Xu Xue-Yu zhe

Phase 4

• Conditions: acute myocardial infarction

• Registration Number: ITMCTR2000002922
• Lead Sponsor: The second affiliated hospital of tianjin university of traditional Chinese medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. aged 35-70 years old;
2. patients with acute myocardial infarction, 15 days to 3 months after clinical diagnosis and treatment;
3. the subject's condition was stable within 15 days;
4. TCM syndrome type is identified as qi deficiency and blood stasis:
(1) main symptoms: chest tightness, chest pain 2) secondary symptoms (blood stasis: purple and dark lips, complexion or claw plate;The tongue is purple or dark or has petechiae or ecchymosis;The veins under the tongue are coarse; Pulse acerbity or sink string, string late;
(2) gas deficiency: palpitations and shortness of breath; God languishes; Easy to sweat, moving is aggravated;Complexion white; Tongue is weak; Teeth marks on the side of tongue; Weak pulse;
5. voluntarily sign the informed consent;
6. healthy group: aged 35 to 70 years old; Did not take any drugs or participate in other clinical trials within 3 months; no coronary heart disease, metabolic disease and other diseases; voluntary signing of informed consent.

Exclusion Criteria

(1) patients with congenital heart disease, heart valve disease, aneurysm, allergic constitution, metabolic diseases (except diabetes), severe infection, severe liver and kidney dysfunction, and a history of cerebrovascular disease;(2) women of child-bearing age who have planned to become pregnant within 2 years (defined as all women of child-bearing age who are physically capable of becoming pregnant) and women who have become pregnant;
(3) those who have participated in any drug clinical trial within the first 3 months;
(4) the researcher judged that the survival of the patients should not exceed 6 months;
(5) patients with severe neurological diseases (alzheimer's disease, progressive stage of Parkinson's disease), lower limb disability or deaf-mute;
(6) patients with a previous history of tumor or current tumor, or confirmed by pathological examination to have precancerous lesions;
(7) patients who have been found to have a malignant mass by examination (physical examination, X-ray examination or b-ultrasound examination or other means), or who have been found to have endocrine activity, hyperplasia glands or adenoma affecting heart or endocrine function, such as pheochromocytoma, goiters, etc.;
(8) in the judgment of the investigator, the patient is unable to complete the study or comply with the requirements of the study (due to management reasons or other special reasons);
(9) healthy subjects: pregnant women; Drug use in the first 3 months; participated in other clinical trials; In the judgment of the investigator, the patient is unable to complete the study or comply with the requirements of the study (due to management reasons or other special reasons).

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
two dimensional echocardiogram ;scale;Electrocardiograph;